Results 251 to 260 of about 518,541 (308)
Some of the next articles are maybe not open access.
Overhauling oversight—European drug legislation
Nature Biotechnology, 2005At the end of next month, the European Medicines Agency (EMEA) will implement a new legislative framework and several provisions that seek to provide incentives and streamline regulatory oversight of certain monoclonal antibodies and other biologic products.
openaire +2 more sources
Generic legislation of new psychoactive drugs
Journal of Psychopharmacology, 2013New psychoactive drugs (NPDs, new psychoactive substances) enter the market all the time. However, it takes several months to ban these NPDs and immediate action is generally not possible. Several European countries and drug enforcement officers insist on a faster procedure to ban NPDs.
van Amsterdam, J +2 more
openaire +4 more sources
The New Medicare Prescription-Drug Legislation
New England Journal of Medicine, 2004In terms of dollars, the number of people affected, and the political stakes involved, the Medicare prescription-drug bill is the most important health care legislation passed by Congress since the enactment of Medicare and Medicaid in 1965. The six-month roller-coaster ride taken by the legislation made its passage all the more dramatic and surprising.
openaire +2 more sources
Some Chemical Aspects of Drug Legislation
Journal of the Forensic Science Society, 1967Official chemical advice in drafting the schedules to drug legislation may be based on limited explicit descriptions of regulated substances, or unlimited generic entries, or a combination of both. Non-proprietary names or chemical titles are preferred for known structures ; descriptions of origin and breakdown products may define structurally unknown ...
openaire +2 more sources
No comparative drug efficacy without legislation
BMJ, 2011Data on the comparative efficacy of drugs—or relative efficacy, as it is termed in the EU1—are certainly needed.2 Apart from the pitfalls addressed by Sorenson and colleagues,2 the political reality is that comparative efficacy is required for national reimbursement decisions, which, not surprisingly, are fiercely defended by member states. In 2009 the
openaire +2 more sources
An Orphan Drug Legislation System
2015Orphan drugs are a treatment for rare diseases. From that, comes the importance of orphan drug development and discovery. For an orphan drug to be approved by the FDA, it does not have to be similar to any approved orphan drug. So chemists opinions are important to determine the probability of similarity.
Ahmed Abdel Aziz +5 more
openaire +1 more source
Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies
Ca-A Cancer Journal for Clinicians, 2022Paolo Tarantino +2 more
exaly
Cancer epigenetics in clinical practice
Ca-A Cancer Journal for Clinicians, 2023Veronica Davalos, Manel Esteller
exaly
Legislation on drug control and drug abuse
1982Efforts to control the use of psychoactive substances have been recorded since earliest times. In the classical Greek and Roman periods, mention is made of alcohol excesses, and in Asia Minor and Assyria even earlier use of cannabis is described. Opium, primarily as a medicine, was also known and used, and introduced into China and India in the 8th and
openaire +1 more source